Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: Can we safely transplant patients with impaired ejection fraction?

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 603-607

  Tang, W H W ^a   Thomas, S ^b   Kalaycio, M ^c   Sobecks, R ^c   Andresen, S ^c   Jarvis, S ^c   Rybicki, L ^a   Pohlman, B ^c   Francis, G S ^a   Bolwell, B J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Autologous stem cell transplantation; Hodgkin's disease; Left ventricular ejection fraction; Non Hodgkin's lymphoma

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADULT; BONE MARROW TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 5044247611     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704610     Document Type: Article

References (13)

1. Buja LM, Ferrans VJ, Graw RGJ. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol 1976; 7: 17-45.
2. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-98.
3. Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-2069.
4. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 2001; 28: 283-287.
5. Fujimaki K, Maruta A, Yoshida M et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001; 27: 307-310.
6. Lehmann S, Isberg B, Ljungman P et al. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 187-192.
7. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 2003; 32: 853-861.
8. Bearman SI, Petersen FB, Schor RA. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
9. Hetenstein B, Stefanic M, Schmeiser T. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.
10. Jain B, Floreani AA, Anderson JR. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. Bone Marrow Transplant 1996; 17: 561-568.
11. Zangari M, Henzlova MJ, Ahmad S. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. Bone Marrow Transplant 1999; 23: 917-920.
12. Goldberg SL, Klumpp TR, Magdalinski AJ et al. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16: 3796-3802.
13. Brockstein BE, Smiley C, Al-Sadir J et al. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000; 25: 885-894.